To optimize drug delivery and processing, APIs are combined with several functional excipient categories:
The European Pharmacopoeia (Ph. Eur.) is the definitive regulatory gateway for ensuring the quality, safety, and efficacy of medicines across Europe and beyond. Maintained by the European Directorate for the Quality of Medicines & HealthCare (EDQM), its standards are legally binding in member states. Among its numerous entries, stands as one of the most critical general monographs. It establishes the foundational quality framework for the most widely manufactured and consumed pharmaceutical dosage form in the world.
According to the monograph, tablets are solid preparations, each containing a single dose of one or more active substances. They are primarily obtained by compressing uniform volumes of particles but can also be manufactured via extrusion, moulding, or freeze-drying (lyophilisation).
The monograph dictates that the excipients used must be safe, non-toxic, and must not adversely affect the therapeutic efficacy or bioavailability of the active pharmaceutical ingredient (API). Excipients typically include diluents, binders, disintegrants, glidants, lubricants, and coloring or flavoring agents. Minimizing Microbial Contamination
This test measures the tablet's ability to withstand abrasion during packaging and transport. A sample of tablets is rotated in a drum for a set time (usually 100 rotations).
Compliance with the Ph. Eur. monograph for tablets (0478) is essential for manufacturers who want to market their products in Europe. Regulatory authorities, such as the European Medicines Agency (EMA), require manufacturers to demonstrate that their products meet the requirements of the Ph. Eur. monograph.
: Assessed via general chapter 2.9.7 to ensure tablets do not crumble or break during processing or transport.
This article provides an in-depth analysis of Ph. Eur. Monograph 0478, exploring its scope, core quality requirements, critical testing methodologies, and its profound impact on pharmaceutical manufacturing and regulatory compliance. 1. Scope and Definition of Monograph 0478
The monograph sets GMP-related principles for manufacture:
European Pharmacopoeia (Ph. Eur.) Monograph Tablets (0478): The Definitive Standard for Solid Oral Dosage Forms
This blog post provides an overview of the , which serves as the legally binding standard for tablets marketed in signatory states.
: Since January 2018, revised standards mandate a suitable dissolution test for immediate-release forms unless otherwise justified.
Tablets must be examined visually to ensure they are not broken, have a smooth surface (unless scored), and are free from obvious defects like cracks or spots.
To optimize drug delivery and processing, APIs are combined with several functional excipient categories:
The European Pharmacopoeia (Ph. Eur.) is the definitive regulatory gateway for ensuring the quality, safety, and efficacy of medicines across Europe and beyond. Maintained by the European Directorate for the Quality of Medicines & HealthCare (EDQM), its standards are legally binding in member states. Among its numerous entries, stands as one of the most critical general monographs. It establishes the foundational quality framework for the most widely manufactured and consumed pharmaceutical dosage form in the world.
According to the monograph, tablets are solid preparations, each containing a single dose of one or more active substances. They are primarily obtained by compressing uniform volumes of particles but can also be manufactured via extrusion, moulding, or freeze-drying (lyophilisation).
The monograph dictates that the excipients used must be safe, non-toxic, and must not adversely affect the therapeutic efficacy or bioavailability of the active pharmaceutical ingredient (API). Excipients typically include diluents, binders, disintegrants, glidants, lubricants, and coloring or flavoring agents. Minimizing Microbial Contamination European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478-
This test measures the tablet's ability to withstand abrasion during packaging and transport. A sample of tablets is rotated in a drum for a set time (usually 100 rotations).
Compliance with the Ph. Eur. monograph for tablets (0478) is essential for manufacturers who want to market their products in Europe. Regulatory authorities, such as the European Medicines Agency (EMA), require manufacturers to demonstrate that their products meet the requirements of the Ph. Eur. monograph.
: Assessed via general chapter 2.9.7 to ensure tablets do not crumble or break during processing or transport. To optimize drug delivery and processing, APIs are
This article provides an in-depth analysis of Ph. Eur. Monograph 0478, exploring its scope, core quality requirements, critical testing methodologies, and its profound impact on pharmaceutical manufacturing and regulatory compliance. 1. Scope and Definition of Monograph 0478
The monograph sets GMP-related principles for manufacture:
European Pharmacopoeia (Ph. Eur.) Monograph Tablets (0478): The Definitive Standard for Solid Oral Dosage Forms Among its numerous entries, stands as one of
This blog post provides an overview of the , which serves as the legally binding standard for tablets marketed in signatory states.
: Since January 2018, revised standards mandate a suitable dissolution test for immediate-release forms unless otherwise justified.
Tablets must be examined visually to ensure they are not broken, have a smooth surface (unless scored), and are free from obvious defects like cracks or spots.